Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Posaconazole Plus Pembrolizumab and Chemotherapy Vs Pembrolizumab and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06802757
- Locations
- 🇨🇳
Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
- Conditions
- Lung Cancer, Small Cell
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 1430
- Registration Number
- NCT06780826
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerNeoadjuvant
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT06890338
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT06875310
- Locations
- 🇲🇽
Local Institution - 0638, Puebla, Mexico
🇧🇪Local Institution - 0215, Hasselt, Limburg, Belgium
🇲🇽Local Institution - 0181, Puebla, Mexico
A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT06868836
- Locations
- 🇨🇳
Guangdong Provicial People's Hospital, Guangzhou, Guangdong, China
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Furmonertinib Mesylate
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT06868732
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
- Conditions
- Recurrent or Metastatic Cervical Cancer
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06859775
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 43
- Registration Number
- NCT06845319
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 78
- Registration Number
- NCT06843447
- Locations
- 🇮🇱
Rambam Health Care Campus ( Site 0202), Haifa, Israel
🇮🇱Shaare Zedek Medical Center ( Site 0201), Jerusalem, Israel
🇮🇱Sheba Medical Center ( Site 0200), Ramat Gan, Israel
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT06841354
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, Nevada, United States
🇺🇸Renown Regional Medical Center ( Site 0005), Reno, Nevada, United States
🇮🇱Rambam Health Care Campus ( Site 3700), Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.